Mesoblast Limited (F:LWB) — Market Cap & Net Worth
Market Cap & Net Worth: Mesoblast Limited (LWB)
Mesoblast Limited (F:LWB) has a market capitalization of $1.86 Billion (€1.59 Billion) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #6527 globally and #957 in its home market, demonstrating a -4.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mesoblast Limited's stock price €1.28 by its total outstanding shares 1290269798 (1.29 Billion). Analyse Mesoblast Limited (LWB) cash conversion ratio to see how efficiently the company converts income to cash.
Mesoblast Limited Market Cap History: 2015 to 2026
Mesoblast Limited's market capitalization history from 2015 to 2026. Data shows growth from $867.97 Million to $1.93 Billion (1.90% CAGR).
Mesoblast Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mesoblast Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
128.94x
Mesoblast Limited's market cap is 128.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $698.72 Million | $42.55 Million | -$4.13 Million | 16.42x | N/A |
| 2017 | $677.45 Million | $2.41 Million | -$76.81 Million | 280.87x | N/A |
| 2018 | $524.94 Million | $17.34 Million | -$35.29 Million | 30.27x | N/A |
| 2019 | $1.93 Billion | $16.72 Million | -$89.80 Million | 115.47x | N/A |
| 2020 | $2.07 Billion | $32.16 Million | -$77.94 Million | 64.27x | N/A |
| 2021 | $1.27 Billion | $7.46 Million | -$98.81 Million | 169.94x | N/A |
| 2022 | $813.06 Million | $10.21 Million | -$91.35 Million | 79.63x | N/A |
| 2023 | $247.39 Million | $7.50 Million | -$81.89 Million | 32.98x | N/A |
| 2024 | $2.59 Billion | $5.90 Million | -$87.96 Million | 439.61x | N/A |
| 2025 | $2.22 Billion | $17.20 Million | -$102.14 Million | 128.94x | N/A |
Competitor Companies of LWB by Market Capitalization
Companies near Mesoblast Limited in the global market cap rankings as of May 4, 2026.
Key companies related to Mesoblast Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Mesoblast Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Mesoblast Limited's market cap moved from $867.97 Million to $ 1.93 Billion, with a yearly change of 1.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.93 Billion | -13.10% |
| 2025 | €2.22 Billion | -14.53% |
| 2024 | €2.59 Billion | +948.78% |
| 2023 | €247.39 Million | -69.57% |
| 2022 | €813.06 Million | -35.83% |
| 2021 | €1.27 Billion | -38.69% |
| 2020 | €2.07 Billion | +7.03% |
| 2019 | €1.93 Billion | +267.82% |
| 2018 | €524.94 Million | -22.51% |
| 2017 | €677.45 Million | -3.04% |
| 2016 | €698.72 Million | -19.50% |
| 2015 | €867.97 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Mesoblast Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.86 Billion USD |
| MoneyControl | $1.86 Billion USD |
| MarketWatch | $1.86 Billion USD |
| marketcap.company | $1.86 Billion USD |
| Reuters | $1.86 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more